Cadisegliatin

DB18886InvestigationalSmall molecule

Cadisegliatin is under investigation in clinical trial NCT06334133 (Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes).

Chemical structure of Cadisegliatin
Mechanism
Curator reviewed
Formula / weight
C21H33N3O4S2 · 455.63 g/mol (avg)
Also known as
[(2-{[cyclohexyl(trans-4-propoxycyclohexyl)carbamoyl]amino}-1,3-thiazol-5-yl)sulfanyl]acetic acid · 2-((2-(3-cyclohexyl-3-((1r,4r)-4-propoxycyclohexyl)ureido)thiazol-5-yl)thio)acetic acid · Acetic acid, 2-[[2-[[[cyclohexyl(trans-4-propoxycyclohexyl)amino]carbonyl]amino]-5-thiazolyl]thio]-
Code names
NN-9108 · NNC 80-3315 · TTP-00223399 · TTP-399

Resolves to

Compound
UNII98S8SH8UNFCAS859525-02-3ChEMBLCHEMBL5095262
Structure
InChIKeyHPGJSAAUJGAMLV-QAQDUYKDSA-NSMILESCCCO[C@H]1CC[C@@H](CC1)N(C1CCCCC1)C(=O)NC1=NC=C(SCC(O)=O)S1
Targets
P35557GCK

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Cadisegliatin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In